ArticleCureus2026
Outcomes of Surgical Pulmonary Embolectomy for Acute Pulmonary Embolism: A 14-Year Single-Centre Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis retrospective single-centre cohort study investigates the outcomes of surgical pulmonary embolectomy for high-risk acute pulmonary embolism (PE) at our institution over a 14-year period.
methodsWe conducted a retrospective review of medical records for 13 consecutive patients who underwent surgical pulmonary embolectomy (SPE) between 2006 and 2020. Data collected included patient demographics, comorbidities, pre-operative assessments (echocardiography, computed tomography pulmonary angiography (CTPA) findings), indications for SPE, surgical details, post-operative complications, and 12-month survival.
resultsThe study cohort comprised 13 patients, predominantly male (69.2%), with a median age of 47 years. Comorbidities varied, with one patient lacking identifiable risk factors. Pre-operative assessment demonstrated right ventricular dysfunction identified on echocardiography, CTPA, or both modalities. Indications for SPE included high-risk PE (76.9%), contraindication to thrombolysis (7.7%), and persistent haemodynamic instability despite thrombolysis (15.4%). All procedures were performed via median sternotomy with cardiopulmonary bypass. The median ICU stay was two days. In-hospital mortality was 23.1%. Post-operative complications included atrial fibrillation (30.8%), cardiac tamponade (15.4%), and residual PE (23.1%). Twelve-month survival was 76.9%.
conclusionOur 14-year experience demonstrates that SPE remains a viable and critical intervention for select high-risk PE patients, particularly in a specialised tertiary care setting. Despite the critical nature of the patient population, the observed outcomes align with contemporary reports, suggesting improved survival with timely and expert care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.